Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (Q64360391)
Jump to navigation
Jump to search
article by Martin R Gaudinski et al published 2 March 2019 in The Lancet
Language | Label | Description | Also known as |
---|---|---|---|
English | Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study |
article by Martin R Gaudinski et al published 2 March 2019 in The Lancet |
Statements
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (English)
0 references
2 March 2019
0 references
393
0 references
10174
0 references
889-898
0 references
1 reference